Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Multiple Subcutaneous Administration of UBT37034 Injection in Overweight/Obesity Trial Participants

NCT07873645 is registered in ClinicalTrials.gov with The United Bio-Technology (Hengqin) Co., Ltd. as lead sponsor.

NCT NCT07873645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07873645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Multiple Subcutaneous Administration of UBT37034 Injection in Overweight/Obesity Trial Participants
Lead sponsor
The United Bio-Technology (Hengqin) Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
August 31, 2027
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

overweight , obesity